The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Open accessAbstract
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944 patients with various MDS subtypes were screened for known/putative mutations/deletions in 104 genes using targeted deep sequencing and array-based genomic hybridization. In total, 845/944 patients (89.5%) harbored at least one mutation (median, 3 per patient; range, 0-12). Forty-seven genes were significantly mutated with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 mutated in >10% of cases. Many mutations were associated with higher risk groups and/or blast elevation. Survival was investigated in 875 patients. By univariate analysis, 25/48 genes (resulting from 47 genes tested significantly plus PRPF8) affected survival (P<0.05). The status of 14 genes combined with conventional factors revealed a novel prognostic model ('Model-1') separating patients into four risk groups ('low', 'intermediate', 'high', 'very high risk') with 3-year survival of 95.2, 69.3, 32.8, and 5.3% (P<0.001). Subsequently, a 'gene-only model' ('Model-2') was constructed based on 14 genes also yielding four significant risk groups (P<0.001). Both models were reproducible in the validation cohort (n=175 patients; P<0.001 each). Thus, large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dysregulated iron metabolism is a hallmark of a large subset of MDS with ringed sideroblasts (MDS-RS), characterized by aberrant iron accumulation in erythroblast mitochondria and accounting for ~30% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations are detected in approximately 10%-20% of patients with de novo myelodysplastic syndromes (MDS)1-4 or acute myeloid leukemia (AML)5,6 and 30%-40% of patients with therapy-related disease.7”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of MDS, eprenetapopt is currently only indicated in ~7% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Haferlach et al. 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Self-citationDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Several Tests for Model Specification in the Presence of Alternative Hypotheses
Davidson, R., & MacKinnon, J. G. (1981) · Econometrica · doi:10.2307/1911522 · Cited by 1,747
Flagged first, then by citations
Research works printed but not linked: 1
- Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et al. Myelodysplastic syndromes. In: Jaffe ES, Harris N, Stein H, Vardiman J, eds World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon, France, 2001; pp 61–73.
Cited by
Sorted by citations
Items 601–700 of 999
Margolskee, E. M., Hasserjian, R. P., Hassane, D. C., Tam, W., Mathew, S., Ok, C. Y., Wang, S. A., Oak, J. S., Arber, D. A., & Orazi, A. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqx043 · Cited by 19
Kim, S. Y., Kim, K., Hwang, B., Im, K., Park, S. N., Kim, J., Hwang, S. M., Bang, D., & Lee, D. S. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.09.001 · Cited by 19
Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia
Strickland, S. A., Shaver, A. C., Byrne, M. P., Daber, R. D., Ferrell, P. B., Head, D. R., Mohan, S. R., Mosse, C. A., Moyo, T. K., Stricker, T. P., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2017.12.012 · Cited by 19
Cabezón, M., the CETLAM Group, Bargay, J., Xicoy, B., García, O., Borràs, J. M., Tormo, M., Marcé, S., Pedro, C., Valcárcel, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25046 · Cited by 19
Prognostic value of DNMT3A mutations in myelodysplastic syndromes: a meta-analysis
Liang, S., Zhou, X., Pan, H., Yang, Y., Shi, L., & Wang, L. (2019) · Hematology · doi:10.1080/16078454.2019.1657613 · Cited by 20
Oh, Y.-J., Shin, D.-Y., Hwang, S. M., Kim, S., Im, K., Park, H. S., Kim, J.-A., Song, Y. W., Márquez, A., Martin, J. J., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.247 · Cited by 19
Prognostic significance of U2AF1 mutations in myelodysplastic syndromes: a meta-analysis
Li, B., Zou, D., Yang, S., Ouyang, G., & Mu, Q. (2019) · Journal of International Medical Research · doi:10.1177/0300060519891013 · Cited by 18
Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
Pagliuca, S., Gurnari, C., & Visconte, V. (2021) · Cancers · doi:10.3390/cancers13040784 · Cited by 18
Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia
Honda, A., Koya, J., Yoshimi, A., Miyauchi, M., Taoka, K., Kataoka, K., Arai, S., & Kurokawa, M. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.07.005 · Cited by 18
When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?
Osman, A. (2021) · Hematology · doi:10.1182/hematology.2021000272 · Cited by 18
Modeling Myeloid Malignancies Using Zebrafish
Potts, K. S., & Bowman, T. V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00297 · Cited by 18
Diagnostic algorithm for lower-risk myelodysplastic syndromes
Mufti, G. J., McLornan, D. P., van de Loosdrecht, A. A., Germing, U., & Hasserjian, R. P. (2018) · Leukemia · doi:10.1038/s41375-018-0173-2 · Cited by 18
Loss of ASXL1 expression is associated with lymph node metastasis in colorectal cancer
Lee, K., Lee, J., Lee, J., Ahn, B., Paik, S., & Kim, H. (2020) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_822_19 · Cited by 17
Pozdnyakova, O., Niculescu, R. S., Kroll, T., Golemme, L., Raymond, N., Briggs, D., & Kim, A. (2022) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207860 · Cited by 17
Schnegg-Kaufmann, A. S., Thoms, J. A. I., Bhuyan, G. S., Hampton, H. R., Vaughan, L., Rutherford, K. D., Kakadia, P. M., Lee, H. M., Johansson, E. M. V., Failes, T. W., et al. (2022) · Blood · doi:10.1182/blood.2022018602 · Cited by 18
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes
Schulz, E., Aplan, P. D., Freeman, S. D., & Pavletic, S. Z. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010098 · Cited by 17
Jann, J.-C., Hergott, C. A., Winkler, M., Liu, Y., Braun, B., Charles, A. L., Copson, K. M., Barua, S., Meggendorfer, M., Nadarajah, N., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02347-y · Cited by 16
Self-citationAllogeneic stem cell transplantation in myelodysplastic syndromes
Brierley, C. K., & Steensma, D. P. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000217 · Cited by 18
Influence of functional polymorphisms in DNA repair genes of myelodysplastic syndrome
Ribeiro, H. L., Maia, A. R. S., Costa, M. B., Farias, I. R., Borges, D. D. P., de Oliveira, R. T. G., de Sousa, J. C., Magalhães, S. M. M., & Pinheiro, R. F. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.06.008 · Cited by 17
Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender
Patterson-Fortin, J., & Moliterno, A. R. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0411-0 · Cited by 16
Management of older adults with myelodysplastic syndromes (MDS)
Luskin, M. R., & Abel, G. A. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.12.002 · Cited by 17
Karastaneva, A., Nebral, K., Schlagenhauf, A., Baschin, M., Palankar, R., Juch, H., Heitzer, E., Speicher, M. R., Höfler, G., Grigorow, I., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106339 · Cited by 17
Pangallo, J., Kiladjian, J., Cassinat, B., Renneville, A., Taylor, J., Polaski, J. T., North, K., Abdel-Wahab, O. I., & Bradley, R. K. (2020) · Blood · doi:10.1182/blood.2019002894 · Cited by 19
Crisà, E., Kulasekararaj, A. G., Ademà, V., Such, E., Schanz, J., Haase, D. T., Shirneshan, K., Best, S., Mian, S. A., Kizilors, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0728-x · Cited by 18
Dysregulated minor intron splicing in cancer
Nishimura, K., Yamazaki, H., Zang, W., & Inoue, D. (2022) · Cancer Science · doi:10.1111/cas.15476 · Cited by 15
Splicing dysregulation in human hematologic malignancies: beyond splicing mutations
Kesel, J. D., Fijałkowski, I., Taylor, J., & Ntziachristos, P. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.06.006 · Cited by 17
Yoon, J., Jeon, Y., Yahng, S., Shin, S., Lee, S., Cho, B., Lee, D., Eom, K., Kim, H., Lee, S., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.11.008 · Cited by 17
Chronic Myelomonocytic Leukaemia
Himmelmann, A. W. (2016) · InTech eBooks · doi:10.5772/63193 · Cited by 17
Prognostic Markers of Myelodysplastic Syndromes
Veryaskina, Y. A., Titov, S. E., Kovynev, I. B., Pospelova, T. I., & Zhimulev, I. F. (2020) · Medicina · doi:10.3390/medicina56080376 · Cited by 17
New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities
Zahr, A. A., Bernabe, C., Wozney, J. L., Prébet, T., & Zeidan, A. M. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1135047 · Cited by 17
van Zeventer, I. A., de Graaf, A. O., van der Klauw, M. M., Vellenga, E., van der Reijden, B. A., Schuringa, J. J., Diepstra, A., Malcovati, L., Jansen, J. H., & Huls, G. A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004355 · Cited by 16
Trsová, I., Hruštincová, A., Krejčík, Z., Kundrát, D., Holoubek, A., Štaflová, K., Janstová, L., Vaníková, Š., Szikszai, K., Kléma, J., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13486 · Cited by 16
Kubasch, A. S., Péterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H. L., Sébert, M., Chermat, F., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02029-1 · Cited by 16
Volkert, S., Haferlach, T., Holzwarth, J., Zenger, M., Kern, W., Staller, M., Nagata, Y., Yoshida, K., Ogawa, S., Schnittger, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.257 · Cited by 16
Self-citationClinical significance of acquired somatic mutations in aplastic anaemia
Marsh, J., & Mufti, G. J. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1972-8 · Cited by 16
Haider, M., Duncavage, E. J., Afaneh, K. F., Bejar, R. L., & List, A. F. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175397 · Cited by 16
Insights from structures of cancer-relevant pre-mRNA splicing factors
Kielkopf, C. L. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.008 · Cited by 17
Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms
Chao, M. M., Thomay, K., Goehring, G., Włodarski, M. W., Pastor, V. M. L., Schlegelberger, B., Schindler, D., Kratz, C. P., & Niemeyer, C. M. (2017) · Klinische Pädiatrie · doi:10.1055/s-0043-117046 · Cited by 17
ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion
Madan, V., Han, L., Hattori, N., Teoh, W. W., Mayakonda, A., Sun, Q., Ding, L., Nordin, H. B. M., Lim, S. L., Shyamsunder, P., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.189928 · Cited by 18
Self-citationLow‐Grade Myelodysplastic Syndromes with Preserved CD34+ B‐Cell Precursors (CD34+ Hematogones)
Chen, Z., Ok, C. Y., Wang, W., Goswami, M., Tang, G., Routbort, M. J., Jorgensen, J. L., Medeiros, L. J., & Wang, S. A. (2019) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21830 · Cited by 16
Gene mutation profile in patients with acquired pure red cell aplasia
Long, Z., Li, H., Du, Y., Chen, M., Zhuang, J., & Han, B. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04154-8 · Cited by 15
Santini, V., Fenaux, P., Giagounidis, A. A. N., Platzbecker, U., List, A. F., Haferlach, T., Zhong, J., Wu, C., Mavrommatis, K., Beach, C. L., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0961-3 · Cited by 16
Self-citationOk, C. Y., Trowell, K. T., Parker, K. G., Moser, K. A., Weinberg, O. K., Rogers, H. J., Reichard, K. K., George, T. I., Hsi, E. D., Bueso-Ramos, C., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0624-y · Cited by 17
Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis
He, W., Zhao, C., & Hu, H. (2020) · Hematology · doi:10.1080/16078454.2020.1858598 · Cited by 16
Chromatin-Spliceosome Mutations in Acute Myeloid Leukemia
Ochi, Y., & Ogawa, S. (2021) · Cancers · doi:10.3390/cancers13061232 · Cited by 16
Self-citationJohansson, U., McIver‐Brown, N., Cullen, M. J., Duetz, C., Dunlop, A. S., Oelschlägel, U., Psarra, K., Subirá, D., & Westers, T. M. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22048 · Cited by 16
Förster, A., Decker, M., Schlegelberger, B., & Ripperger, T. (2022) · Cancers · doi:10.3390/cancers14143431 · Cited by 17
Gaulin, C., Kelemen, K., & Yi, C. A. (2022) · Life · doi:10.3390/life12081135 · Cited by 16
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes
Komrokji, R. S., Aguirre, L. E. E., Ali, N. E. A., Hussaini, M., Sallman, D. A., Rollison, D. E. M., & Padron, E. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007504 · Cited by 16
Maciejewski, J. P., & Balasubramanian, S. K. (2017) · Hematology · doi:10.1182/asheducation-2017.1.66 · Cited by 15
Du, M., Zhou, F., Jin, R., Hu, Y., & Mei, H. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.03.001 · Cited by 16
Liang, J., Na, X., Meng, L., He, L., Shu, T., Fang, Y., Zhang, B., Zhao, Z., Guo, C., Li, J., et al. (2025) · MedComm · doi:10.1002/mco2.70245 · Cited by 15
Sato, N., Goyama, S., & Kitamura, T. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04038-5 · Cited by 18
Maes, B., Willemse, J., Broekmans, A., Smets, R., Cruys, B., Put, N., Madoe, V., Janssen, M. A. C., Soepenberg, O., Bries, G., et al. (2017) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12709 · Cited by 15
Knockdown of spliceosome U2AF1 significantly inhibits the development of human erythroid cells
Zhang, J., Zhao, H., Wu, K., Peng, Y., Han, X., Zhang, H., Liang, L., Chen, H., Hu, J., Qu, X., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14370 · Cited by 15
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations
Venable, E. R., Chen, D., Chen, C. P., Bessonen, K., Nguyen, P. L., Oliveira, J. L., Reichard, K. K., Hoyer, J. D., Althoff, S. D., Roh, D. J., et al. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab010 · Cited by 15
Hoermann, G. (2022) · Diagnostics · doi:10.3390/diagnostics12071613 · Cited by 17
Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
Ambinder, A. J., & Dezern, A. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1033534 · Cited by 16
RNA splicing alterations in lung cancer pathogenesis and therapy
Yan, Y., Ren, Y., Bao, Y., & Wang, Y. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.04.004 · Cited by 16
Dezern, A. E., & Greenberg, P. L. (2023) · Blood · doi:10.1182/blood.2023020081 · Cited by 15
Dimitriou, M., Blanco, T. M., Tobiasson, M., Mazzi, S., Lehander, M., Högstrand, K., Karimi, M., Walldin, G., Jansson, M., Vonlanthen, S., et al. (2023) · Blood · doi:10.1182/blood.2023022851 · Cited by 16
Biological relevance of alternative splicing in hematologic malignancies
Szelest, M., & Giannopoulos, K. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00839-2 · Cited by 16
Martín, I., Such, E., Navarro, B., Vicente, A., López‐Pavía, M., Ibáñez, M., Tormo, M., Villamón, E., Gómez‐Seguí, I., Luna, I., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1246725 · Cited by 15
Somatic mosaicism in chronic myeloid leukemia in remission
Mitani, K., Nagata, Y., Sasaki, K., Yoshida, K., Chiba, K., Tanaka, H., Shiraishi, Y., Miyano, S., Makishima, H., Nakamura, Y., et al. (2016) · Blood · doi:10.1182/blood-2016-06-723494 · Cited by 15
Self-citationCheng, Z., Hu, K., Tian, L., Dai, Y., Pang, Y., Cui, W., Zhao, H., Qin, T., Han, Y., Hu, N., et al. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0013-6 · Cited by 15
Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal
Xu, J. J., Smeets, M. F. M. A., Tan, S. Y., Wall, M., Purton, L. E., & Walkley, C. R. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.11.001 · Cited by 15
Takaoka, K., Kawazu, M., Koya, J., Yoshimi, A., Masamoto, Y., Maki, H., Toya, T., Kobayashi, T., Nannya, Y., Arai, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0385-0 · Cited by 15
Energy metabolism and drug response in myeloid leukaemic stem cells
Bencomo-Alvarez, A. E., Rubio, A. J., Gonzalez, M. A., & Eiring, A. M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16074 · Cited by 18
Dimopoulos, K., Hansen, O. K., Sjø, L. D., Saft, L., Schjødt, I. M., Hansen, J. W., & Grønbæk, K. (2019) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21842 · Cited by 14
[Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing].
Li, B.-X., Wang, J. Y., Liu, J. Q., Shi, Z. X., Peng, S. L., Huang, H., Qin, T. J., Xu, Z., Zhang, Y., Fang, L. W., et al. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.12.002 · Cited by 15
Detectable mutations precede late myeloid neoplasia in aplastic anemia
Patel, B. A., Ghannam, J. Y., Groarke, E. M., Goswami, M., Dillon, L. W., Gutierrez‐Rodrigues, F., Rios, O. J., Raffo, D. Q., Lotter, J., Young, N. S., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.263046 · Cited by 15
Zhou, X., Friedlander, S., Kupperman, E., Sedarati, F., Kuroda, S., Hua, Z., Yuan, Y., Yamamoto, Y., Faller, D. V., Haikawa, K., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.12972 · Cited by 15
Applications of next-generation sequencing in hematologic malignancies
Ramkissoon, L. A., & Montgomery, N. D. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.02.006 · Cited by 14
Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients
Lee, W., Lin, C., Tsai, C., Tseng, M., Kuo, Y., Liu, M.-C., Tang, J., Sun, H., Chuang, Y., Chou, W., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26734 · Cited by 15
Huang, Y.-J., Chen, J., Yan, M., Davis, A. G., Miyauchi, S., Chen, L., Hao, Y., Katz, S., Bejar, R. L., Abdel-Wahab, O. I., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007804 · Cited by 17
Marques, F. K., & Sabino, A. D. P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113905 · Cited by 15
Acha, P., Mallo, M., & Solé, F. G. (2022) · Cancers · doi:10.3390/cancers14225531 · Cited by 14
Odenike, O. M., Onida, F., & Padron, E. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e398 · Cited by 16
Impact of TET2 deficiency on iron metabolism in erythroblasts
Inokura, K., Fujiwara, T., Saito, K., Iino, T., Hatta, S., Okitsu, Y., Fukuhara, N., Onishi, Y., Ishizawa, K., Shimoda, K., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.01.002 · Cited by 16
Martin, R., Acha, P., Ganster, C., Palomo, L., Dierks, S., Fuster‐Tormo, F., Mallo, M., Ademà, V., Gómez‐Marzo, P., de Haro, N., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25089 · Cited by 15
A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations
Li, X., Xu, F., Wu, L., Zhao, Y., Guo, J., He, Q., Zhang, Z., Chang, C., & Wu, D. (2020) · Scientific Reports · doi:10.1038/s41598-019-55540-w · Cited by 15
Genetic basis of myelodysplastic syndromes
Ogawa, S. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.009 · Cited by 15
Self-citationKawata, E., Lazo‐Langner, A., Xenocostas, A., Hsia, C. C., Howson‐Jan, K., Deotare, U., Saini, L., Yang, P., Broadbent, R., Levy, M. A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16891 · Cited by 15
TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics
Guan, Y., Hasipek, M., Tiwari, A. D., Maciejewski, J. P., & Jha, B. K. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.002 · Cited by 15
Shah, M. V., Hung, K., Baranwal, A., Wechalekar, G., Al‐Kali, A., Toop, C. R., Greipp, P. T., Kutyna, M., Matin, A., Ładoń, D., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01290-0 · Cited by 15
BMT for Myelodysplastic Syndrome: When and Where and How
Jain, A. G., & Elmariah, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.771614 · Cited by 14
Zeidan, A. M., Bewersdorf, J. P., Hasle, V., Shallis, R. M., Thompson, E. G., Menezes, D. L. D., Rose, S., Boss, I. W., Halene, S., Haferlach, T., et al. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241257904 · Cited by 16
Self-citationChristopeit, M., Badbaran, A., Alawi, M., Zabelina, T., Zeck, G., Wolschke, C., Ayuk, F. A., & Kröger, N. M. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12724 · Cited by 14
Morgan, E. A., Lee, M. N., DeAngelo, D. J., Steensma, D. P., Stone, R. M., Kuo, F. C., Aster, J. C., Gibson, C. J., & Lindsley, R. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017011197 · Cited by 13
Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia
Hwang, S. M., Kim, S., Nam, Y., Kim, J., Kim, S., Ahn, Y., Park, Y., Yoon, S., Shin, S., Kwon, S., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106190 · Cited by 14
Targeting Aberrant Splicing in Myelodysplastic Syndromes
Brunner, A. M., & Steensma, D. P. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.10.003 · Cited by 14
Next‐generation sequencing in hypoplastic bone marrow failure: What difference does it make?
Skibenes, S. T., Clausen, I., & Raaschou‐Jensen, K. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13513 · Cited by 12
Stemer, G., Rowe, J. M., & Ofran, Y. (2021) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s236446 · Cited by 14
Schwind, S., Jentzsch, M., Kubasch, A. S., Metzeler, K. H., & Platzbecker, U. (2021) · Neoplasia · doi:10.1016/j.neo.2021.09.002 · Cited by 15
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts
Swoboda, D. M., Kanagal‐Shamanna, R., Brunner, A. M., Cluzeau, T., Chan, O., Ali, N. E. A., Bravo, G. M., Gesiotto, Q., Gavralidis, A., Hunter, A. M., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01486-w · Cited by 15
Nakamizo, A., Miyamatsu, Y., Hirose, H., Amano, T., Matsuo, S., Fujiwara, M., Shimamura, T., & Yoshimoto, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-20613-w · Cited by 15
Bartels, S., Schipper, E., Kreipe, H. H., & Lehmann, U. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133930 · Cited by 14
I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions
Gondek, L. P., & Dezern, A. E. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0224-3 · Cited by 14
Splicing factor mutations in AML
Ogawa, S. (2014) · Blood · doi:10.1182/blood-2014-04-566752 · Cited by 14
Self-citationThe role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification
Milunović, V., Rogulj, I. M., Planinc‐Peraica, A., Bulycheva, E., & Ostojić, S. K. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12735 · Cited by 14
Metadata
- Authors
- Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., Yoshida, K., Roller, A., Nadarajah, N., Shiraishi, Y., Shiozawa, Y., Chiba, K., Tanaka, H., Koeffler, H. P., Klein, H.-U., Dugas, M., Aburatani, H., Kohlmann, A., Miyano, S., Haferlach, C., Kern, W., & Ogawa, S.
- Affiliations
- Munich Leukemia Laboratory (Germany) (DE)
- Kyoto University (JP)
- The University of Tokyo (JP)
- Research Center for Advanced Science and Technology, The University of Tokyo (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Cedars-Sinai Medical Center (US)
- University of Münster (DE)
- Corresponding author
- Haferlach, T
- Ogawa, S
- ORCID
- Venue
- Leukemia
- Published
- 2013-11-13
- Volume
- 28
- Issue
- 2
- Pages
- 241-247
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC3918868
- OpenAlex
- W2026134786
- Cited by
- 1,532
- References
- 32
- Citations by year
- 2026: 56 · 2025: 85 · 2024: 102 · 2023: 132 · 2022: 133 · 2021: 177 · 2020: 167 · 2019: 134 · 2018: 117 · 2017: 136 · 2016: 126 · 2015: 105 · 2014: 56 · 2013: 3
- FWCI
- 69.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- Leukemia (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Funders
- U.S. Public Health Service (08C46598A)
- Japan Society for the Promotion of Science (24390242, 24659458, 21790907, 25670446, 24221011, 23249052)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- myelodysplastic syndrome, somatic mutations, prognostic model, risk stratification, TET2, SF3B1, ASXL1, SRSF2, DNMT3A, RUNX1, PRPF8, survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gene Frequency, Genetic Markers, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Prognosis, Proportional Hazards Models, Polymorphism, Single Nucleotide, Young Adult, Genetic Association Studies, High-Throughput Nucleotide Sequencing, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
